^
    1year
    Yes, exactly, this is why CD117 expression does not confirm leukemia (@SibaElHussein)
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT expression
    1year
    Our #DATA trial now online. Best benefit was seen in transplanted pts A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression https://t.co/x9mqmuexJ5 (@AlkaliDr)
    Clinical
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT expression
    |
    Tasigna (nilotinib) • daunorubicin • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    over1year
    Our prospective trial is out ⁦⁦@AjHematology⁩. DATA regimen in #AML A Phase II Study of Combination Daunorubicin, Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia with KIT Expression https://t.co/DMufqKBTuz (@AlkaliDr)
    Clinical
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT expression
    |
    Tasigna (nilotinib) • daunorubicin • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    3years
    @sanamloghavi this is likely a naive question but do you think that the PL cells with abnormal CD123/CD117 expression are a specific feature of post-remission CH or that they may also be present in CH that has not (yet) produced leukemia? (@juliamaxson)
    Clinical
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    KIT expression